Correct Answer: A. Hydralazine
Isosorbide dinitrate (ISDN) combined with hydralazine is the only FDA-approved and guideline-recommended vasodilator combination for symptomatic heart failure, particularly in African Americans and those with reduced ejection fraction (HFrEF). This combination works synergistically: ISDN provides nitric oxide-mediated vasodilation (reducing preload and afterload), while hydralazine prevents nitrate tolerance through its antioxidant properties and direct arterial vasodilation. The landmark V-HeFT II trial demonstrated that ISDN + hydralazine reduced mortality by 34% compared to placebo in HF patients. In Indian clinical practice, this combination is recommended by guidelines for HF management when ACE inhibitors/ARBs are contraindicated or inadequately tolerated. The mechanism is complementary—nitrates cause predominantly venous dilation (reducing preload), while hydralazine causes arterial dilation (reducing afterload), together improving cardiac output and reducing myocardial oxygen demand. This is the only vasodilator pair with robust mortality benefit in HF.
Why the other options are wrong
B. Nimodipine — Nimodipine is a selective cerebral calcium channel blocker used for vasospasm in subarachnoid hemorrhage, not for systemic vasodilation in heart failure. It has no role in HF management and lacks evidence for mortality benefit. NBE trap: students confuse all vasodilators as suitable for HF without recognizing that only specific combinations have proven benefit. C. Nitrendipine — Nitrendipine is a dihydropyridine calcium channel blocker used for hypertension, not HF. Calcium channel blockers (except amlodipine in stable HF) can worsen HF due to negative inotropic effects and are contraindicated in systolic HF. No synergy with ISDN for HF management. D. Minoxidil — Minoxidil is a potassium channel opener used for severe hypertension and androgenetic alopecia, not HF. While it causes vasodilation, it triggers reflex tachycardia and sodium retention, worsening HF. It has no evidence base in HF and is not recommended by any HF guideline.
High-Yield Facts
- ISDN + hydralazine is the only vasodilator combination with proven mortality reduction (34% in V-HeFT II) in HFrEF.
- Hydralazine prevents nitrate tolerance by reducing oxidative stress and maintaining endothelial function during chronic ISDN use.
- Nitrates cause predominantly venous dilation (preload reduction); hydralazine causes arterial dilation (afterload reduction)—complementary mechanisms.
- Dihydropyridine CCBs (nimodipine, nitrendipine) are contraindicated in systolic HF due to negative inotropy; amlodipine is the only safe CCB in stable HF.
- Indian HF guidelines recommend ISDN + hydralazine when ACE-I/ARB are contraindicated or in African American phenotype with HFrEF.
Mnemonics
ISDN-HYD Synergy ISDN (venous) + HYDralazine (arterial) = Inotropic support + HYDration balance. Nitrates ↓ preload, hydralazine ↓ afterload → complementary, not redundant. Nitrate Tolerance Prevention Hydralazine Helps prevent Hyperoxidative damage → maintains Hydrolysis of organic nitrates. Use when ISDN is chronic.
NBE Trap
NBE pairs "vasodilator" broadly with HF to trap students who think any vasodilator works. The key discriminator is proven mortality benefit—only ISDN + hydralazine has this in HFrEF, making it the gold standard combination.
Clinical Pearl
In Indian tertiary care, ISDN + hydralazine is reserved for HFrEF patients intolerant to ACE-I/ARB or with persistent symptoms despite optimal therapy. The combination is particularly effective in African American and South Asian populations with genetic predisposition to HF, and is part of the RNTCP-aligned HF management algorithm in many Indian hospitals.
_Reference: KD Tripathi Pharmacology Ch. 31 (Vasodilators & HF); Harrison's Principles of Internal Medicine Ch. 233 (Heart Failure)_